NCT00283023已完成1 期
Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Number of oligodendrocyte progenitor cell differentiation
研究概览
简要总结
Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.
详细描述
Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 20-65 years of age
- •Informed consent
- •Has elective craniotomy surgery
排除标准
- •HIV, hepatitis, and other central nervous system (CNS) infections
- •Dementia, Alzheimer disease, and neurodegenerative disease
结局指标
主要结局
Number of oligodendrocyte progenitor cell differentiation
时间窗: one month
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
Rajavtihi Neuronal Adult Stem Cells ProjectMultiple SclerosisParkinson's DiseaseAlzheimer's DiseaseNCT00927108Department of Medical Services Ministry of Public Health of Thailand
已完成
1 期
CNS10-NPC-GDNF for the Treatment of ALSAmyotrophic Lateral SclerosisNCT02943850Cedars-Sinai Medical Center18
进行中（未招募）
1 期
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALSAmyotrophic Lateral SclerosisNCT05306457Cedars-Sinai Medical Center16
已完成
不适用
Investigating Endothelial Precursor Cells (EPCs)Central Nervous SystemNCT00067067National Institute of Neurological Disorders and Stroke (NINDS)84
Unknown
2 期
Stem Cell Educator Therapy in Type 1 DiabetesType 1 DiabetesNCT01350219Throne Biotechnologies Inc.100